Sanofi releases new data highlighting leadership in immunology and scientific innovation for patients

Sanofi has announced that they will present 24 abstracts, including: four oral presentations and a late-breaking poster, across approved and investigational medicines at the American Academy of Allergy, Asthma and Immunology Annual Meeting in San Diego, CA from February 28 – March 3, 2025. Presentations include new pooled results from the investigational use of Dupixent in chronic spontaneous urticaria from the LIBERTY-CSU CUPID phase 3 study program, as well as data from disease areas, including asthma, chronic obstructive pulmonary disease, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis, which demonstrate the use of Dupixent in addressing type 2 inflammation across several inflammatory conditions. New analyses from Sanofi’s extensive immunology pipeline, including the RILECSU phase 2 study evaluating rilzabrutinib, a novel oral BTK inhibitor, in adult patients with moderate-to-severe CSU, will also be presented.

Alyssa Johnsen, MD, PhD
Global Therapeutic Area Head, Immunology and Oncology Development
“Our robust presence at AAAAI emphasizes the progress of our clinical development in immunology and underscores our commitment to transforming treatment paradigms in immunoscience. We look forward to sharing these data across multiple disease areas, building upon the body of clinical evidence supporting the breadth of Dupixent in conditions driven by type 2 inflammation and exemplifying the potential of our pipeline medicines.”

---

---

Related Topics and Keywords

Immunology, Sanofi